Archive · 20 Jan 2026
GSK to Acquire RAPT Therapeutics for $2.2 Billion
GSK, a big UK company that makes medicines, is buying RAPT Therapeutics, a smaller US company that develops new treatments for people with inflammatory and immune diseases.
GSK is paying $2.2 billion for RAPT.
This includes $1.9 billion upfront and $58 for each share of RAPT's stock.
The deal is expected to finish by the end of March 2026.
GSK wants to get a program called ozureprubart, which could help people with food allergies by giving them protection every 12 weeks instead of every 2 weeks.
After the news, RAPT's stock price went up a lot, but GSK's stock went down a little.
GSK to acquire RAPT Therapeutics for an equity value of $2.2 billion, with an upfront payment of $1.9 billion.
The deal includes GSK offering $58 per share for RAPT's common stock.
The acquisition is expected to close by the end of the first quarter of 2026.
GSK will gain global rights to RAPT's ozureprubart program, excluding certain regions in China.
RAPT Therapeutics' stock surged over 63% in pre-market trading following the acquisition announcement.
- Who
- GSK Plc and RAPT Therapeutics
- What
- Acquisition of RAPT Therapeutics by GSK
- When
- Announced on 20 January 2026, expected to close by the end of Q1 2026
- Where
- GSK is based in the UK, RAPT Therapeutics is based in California, USA
- Why
- To acquire the ozureprubart program and expand GSK's pipeline in inflammatory and immunologic diseases
- Acquirer
- GSK Plc
- Target
- RAPT Therapeutics
- Deal Value
- $2.2 billion
- Upfront Payment
- $1.9 billion
- Share Price Offered
- $58 per share
- Expected Completion
- End of Q1 2026
- Key Asset Acquired
- Ozureprubart program
- Financial Advisors to GSK
- Evercore
- Legal Counsel to GSK
- A&O Shearman
- Financial Advisors to RAPT
- J.P. Morgan Securities LLC
- Legal Counsel to RAPT
- Cooley LLP
